Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

Summary

The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications